Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 2, Février 2009
Page(s) 161 - 167
Section M/S revues
DOI https://doi.org/10.1051/medsci/2009252161
Publié en ligne 15 février 2009
  1. Sakai LY, Keene DR, Engvall E. Fibrillin, a new 350-kDa glycoprotein, is a component of extracellular microfibrils. J Cell Biol 1986; 103 : 2499–509.
  2. Hollister DW, Godfrey M, Sakai LY, Pyeritz RE. Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. N Engl J Med 1990; 323 : 152–9.
  3. Magenis RE, Maslen CL, Smith L, et al. Localization of the fibrillin (FBN) gene to chromosome 15, band q21.1. Genomics 1991; 11 : 346–51.
  4. Kissin EY, Lemaire R, Korn JH, Lafyatis R. Transforming growth factor beta induces fibroblast fibrillin-1 matrix formation. Arthritis Rheum 2002; 46 : 3000–9.
  5. Itoh S, ten Dijke P. Negative regulation of TGF-beta receptor/Smad signal transduction. Curr Opin Cell Biol 2007; 19 : 176–84.
  6. Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986; 261 : 4337–45.
  7. Isogai Z, Ono RN, Ushiro S, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003; 278 : 2750–7.
  8. Nunes I, Gleizes PE, Metz CN, Rifkin DB. Latent transforming growth factorb binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factorb. J Cell Biol 1997; 136 : 1151–63.
  9. Collod-Beroud G, Le Bourdelles S, Ades L, et al. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat 2003; 22 : 199–208.
  10. Pereira L, Andrikopoulos K, Tian J, et al. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 1997; 17 : 218–22.
  11. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003; 33 : 407–11.
  12. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 2004; 36 : 855–60.
  13. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005; 37 : 275–81.
  14. McGaha T, Saito S, Phelps RG, et al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol 2001; 116 : 136–43.
  15. Sonnylal S, Denton CP, Zheng B, et al. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007; 56 : 334–44.
  16. Allanore Y, Wipff J, Kahan A, Boileau C. Genetic basis of systemic sclerosis. Joint Bone Spine 2007; 74 : 577–83.
  17. Wipff J, Giraud M, Sibilia J, et al. Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. J Rheumatol 2008; 4 : 643–9.
  18. Wallis DD, Tan FK, Kessler R, et al. Fibrillin 1 abnormalities in dermal fibroblast cultures from first-degree relatives of patients with systemic sclerosis (scleroderma). Arthritis Rheum 2004; 50 : 329–32.
  19. Tan FK, Arnett FC, Antohi S, et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 1999; 163 : 1066–72.
  20. Snowden N, Coupes B, Herrick A, et al. Plasma TGF beta in systemic sclerosis: a cross-sectional study. Ann Rheum Dis 1994; 53 : 763–7.
  21. Coker RK, Laurent GJ, Jeffery PK, et al. Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung. Thorax 2001; 56 : 549–56.
  22. Pannu J, Gore-Hyer E, Yamanaka M, et al. An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma. Arthritis Rheum 2004; 50 : 1566–77.
  23. Dong C, Zhu S, Wang T, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002; 99 : 3908–13.
  24. Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56 :323–33.
  25. Sztrymf B, Yaici A, Girerd B, Humbert M. Genes and pulmonary hypertension. Respiration 2007; 74 : 123–32.
  26. Wipff J, Kahan A, Hachulla E, et al. Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 2007; 46 : 622–5.
  27. Boileau C, Jondeau G, Mizuguchi T, Matsumoto N. Molecular genetics of Marfan syndrome. Curr Opin Cardiol 2005; 20 : 194–200.
  28. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312 : 117–21.
  29. Michel JB. Système rénine-angiotensine et remodelage vasculaire. Med Sci (Paris) 2004; 20 : 409–13.
  30. Campistol JM, Inigo P, Larios S, et al. Role of transforming growth factor-beta 1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant 2001; 16 (suppl 1) : 114–6.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.